DSG Capital Advisors LLC Buys 5,090 Shares of AbbVie Inc. $ABBV

Key Points

• DSG Capital Advisors LLC increased its stake in AbbVie by 12.7% in Q4, purchasing an additional 5,090 shares to hold 45,307 shares worth $9.82 million (about 1.5% of its portfolio and its 21st largest holding).
• AbbVie declared a quarterly dividend of $1.73 per share (annualized $6.92, ~3.4% yield) with an ex-dividend date of April 15 and payment on May 15.
• Analysts hold a consensus rating of "Moderate Buy" with an average price target of $253.43; AbbVie recently beat quarterly EPS ($2.71 vs. $2.65), set FY2026 guidance of 14.37–14.57 EPS, and the stock was trading near $204 (down ~2.1%).

DSG Capital Advisors LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 12.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 45,307 shares of the company's stock after purchasing an additional 5,090 shares during the period. AbbVie comprises approximately 1.5% of DSG Capital Advisors LLC's portfolio, making the stock its 21st biggest position. DSG Capital Advisors LLC's holdings in AbbVie were worth $9,820,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ABBV. Wellington Management Group LLP boosted its stake in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the last quarter. Raymond James Financial Inc. boosted its stake in shares of AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of AbbVie by 31.8% in the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company's stock worth $1,685,918,000 after buying an additional 1,758,657 shares during the last quarter. Amundi boosted its stake in shares of AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after buying an additional 1,414,621 shares during the last quarter. Finally, Danske Bank A S purchased a new position in shares of AbbVie in the 3rd quarter worth approximately $279,609,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of research analyst reports. William Blair restated an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. Weiss Ratings restated a "hold (c)" rating on shares of AbbVie in a research note on Wednesday, January 21st. Barclays started coverage on AbbVie in a research note on Thursday, February 19th. They issued an "overweight" rating and a $275.00 target price on the stock. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, Citigroup dropped their price objective on AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $253.43.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RBC and other Wall Street analysts continue to back AbbVie, with RBC maintaining a Buy rating and a $260 price target — a reminder of analyst confidence in the company’s long-term outlook. AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street
• Positive Sentiment: Opinion pieces and value investors are buying recent pullbacks, pointing to AbbVie’s dividend yield and buyback/cash-flow profile as reasons to accumulate on dips. This investor demand can support the stock on weakness. Why I Can’t Stop Buying AbbVie Stock
• Positive Sentiment: AbbVie hit a R&D milestone with partner Nxera, triggering a ~$10M payment — evidence of progress in its neurology collaboration and potential future milestones/royalties if programs advance. Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
• Positive Sentiment: Dividend-focused research lists AbbVie among attractive high-yield names for 2026, reinforcing appeal to income investors and potentially supporting share demand. The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond
• Neutral Sentiment: AbbVie launched a cross-agency marketing push, “PSO Done,” for its psoriasis franchise — a commercial initiative that may aid awareness/sales but is unlikely to move near-term financials materially. AbbVie launches ‘PSO Done’ psoriasis campaign with a cross-agency effort
• Neutral Sentiment: Zacks’ analyst roundup mentions AbbVie among companies with notable analyst coverage, highlighting pipeline and commercial updates — useful context but not a direct catalyst. The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX
• Negative Sentiment: Zacks flagged that AbbVie’s oncology unit faces pressure — declining Imbruvica sales and pricing headwinds could weigh on Q1 top-line growth, a nearer-term revenue risk investors are reacting to. Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth?
• Negative Sentiment: Zacks’ article explains why ABBV fell more than the broader market today, tying the move to the combination of sector rotation, near-term revenue concerns (notably in oncology), and profit-taking after prior gains. Here's Why AbbVie (ABBV) Fell More Than Broader Market

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company's stock.

AbbVie Trading Down 2.1%

AbbVie stock opened at $204.08 on Tuesday. The company has a market cap of $360.85 billion, a price-to-earnings ratio of 86.48, a PEG ratio of 0.74 and a beta of 0.38. The business's 50 day simple moving average is $218.62 and its 200 day simple moving average is $223.14. AbbVie Inc. has a 12 month low of $168.54 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business's quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 14.26 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. AbbVie's dividend payout ratio is currently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.